Table 2.
Crude Late GI Toxicity
| Characteristic | Late GI Toxicity* | p-value | |
|---|---|---|---|
| Grade 0–1 | ≥ grade 2 | ||
| Treatment | 0.002 | ||
| IMRT | 113 (46%) | 10 (22%) | |
| 3DCRT | 134 (54) | 36 (78) | |
| iPSA | 0.9 | ||
| <10 ng/mL | 109 (44) | 19 (32) | |
| 10–20 | 63 (26) | 13 (28) | |
| >20 | 75 (30) | 14 (30) | |
| Gleason Score | 0.97 | ||
| 2–6 | 85 (34) | 15 (33) | |
| 7 | 83 (34) | 16 (35) | |
| 8–10 | 79 (32) | 15 (33) | |
| T stage | 0.06 | ||
| T1 | 77 (31) | 7 (15) | |
| T2 | 111 (45) | 28(61) | |
| T3 | 59 (24) | 11 (24) | |
| AD | 0.9 | ||
| STAD | 104 (42) | 19 (41) | |
| LTAD | 143 (58) | 27 (59) | |
| Diabetes | 40 (16) | 6 (13) | 0.59 |
| Fields | 0.2 | ||
| Prostate alone | 38 (15) | 4 (9) | |
| Prostate + SV | 22 (9) | 2 (4) | |
| Prostate + SV + Lymph nodes | 187 (76) | 40 (87) | |
Abbreviations: GI = gastrointestinal; iPSA= initial prostate specific antigen; AD= androgen deprivation; STAD= short term androgen deprivation; LTAD= long-term androgen deprivation; SV= seminal vesicles
*
Fox Chase modified LENT scale